Withania somnifera Root Extract Enhances Chemotherapy through 'Priming'

Area of Science:

• Pharmacology and Toxicology
• Cancer Biology
• Mitochondrial Biology

Background:

• Withania somnifera (Ashwagandha) extracts possess anti-cancer, anti-inflammatory, and antioxidant properties.
• Modulation of mitochondrial function via oxidative stress is a known mechanism of Withania somnifera.
• Cellular 'priming' is an emerging strategy to enhance cancer cell death.

Purpose of the Study:

• To investigate the 'priming' effect of Withania somnifera root extract on HT-29 colon cancer cells.
• To determine if Withania somnifera enhances the efficacy of the chemotherapeutic agent cisplatin.
• To elucidate the underlying mechanism of 'priming', focusing on mitochondrial function and reactive oxygen species (ROS).

Main Methods:

• Treatment of HT-29 colon cancer cells with Withania somnifera root extract.
• Assessment of cellular response to cisplatin chemotherapy post-treatment.
• Analysis of mitochondrial function and ROS production.
• Comparison of effects on cancerous versus non-cancerous cells.

Main Results:

• Withania somnifera root extract significantly increased the potency of cisplatin in HT-29 colon cancer cells.
• The extract induced mitochondrial dysfunction and elevated ROS levels selectively in cancer cells.
• No similar effects were observed in non-cancerous cells, indicating selectivity.

Conclusions:

• Withania somnifera root extract acts as a 'priming' agent, enhancing chemotherapy effectiveness against colon cancer.
• The mechanism involves selective induction of oxidative stress and mitochondrial dysfunction in cancer cells.
• This suggests a potential therapeutic strategy for improving cancer treatment outcomes with reduced systemic toxicity.